Posted on by Dr Humeira Badsha
“Patients with autoimmune diseases who begin treatment with tumor necrosis factor (TNF) inhibitors are no more likely to develop serious infections than those who start treatment with conventional disease-modifying drugs,” according to research presented at the American College of Rheumatology’s annual meeting and published online Nov. 6 in the Journal of the American Medical Association. Specifically, “among patients with rheumatoid arthritis (RA) who initiated treatment with a TNF inhibitor, the rate of serious infection requiring hospitalizations was 8.16 per 100 person-years,” whereas “the rate among patients with RA who started on a regimen using a conventional agent had a rate of 7.78 per 100 person-years, for an adjusted hazard ratio of 1.05 (95% CI 0.91 to 1.21), which was not significantly different.”
This web site is run by an Arthritis Specialist based in Dubai, United Arab Emirates. On this site you will find news about the latest in arthritis, information about research results in the field, tips and information and diet and exercise, and much more.More
The ORBIT data “showed that patients who have seropositive rheumatoid arthritis are just as likely to respond to rituximab therapy when compared ...Read More
Doctors might one day be able to harvest cells from patients’ noses to produce cartilage that can be transplanted into damaged knee joints, a sma...Read More
© 2013 - 2014 Dr.Humeira Badsha. All rights reserved.